{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:50:36Z","timestamp":1773787836050,"version":"3.50.1"},"publisher-location":"Cham","reference-count":23,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030129224","type":"print"},{"value":"9783030129231","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/5584_2018_328","type":"book-chapter","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T05:54:44Z","timestamp":1548827684000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma"],"prefix":"10.1007","author":[{"given":"Jakub","family":"Kucharz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Dumnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Pastuszczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Ku\u015bnierz-Cabala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Demkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Popko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Wiechno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"328_CR1","unstructured":"American Urological Association (2018) Clear cell renal cell carcinoma: Fuhrman nuclear grade. \n                    https:\/\/www.auanet.org\/education\/auauniversity\/education-products-and-resources\/pathology-for-urologists\/kidney\/renal-cell-carcinomas\/clear-cell-renal-cell-carcinoma-fuhrman-nuclear-grade\n                    \n                  . Accessed on 30 Nov 2018"},{"key":"328_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","volume":"50","author":"P Bono","year":"2011","unstructured":"Bono P, Rautiola J, Utriainen T, Joensuu H (2011) Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50:569\u2013573","journal-title":"Acta Oncol"},{"issue":"4","key":"328_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12032-017-0928-z","volume":"34","author":"A Buda\u2013Nowak","year":"2017","unstructured":"Buda\u2013Nowak A, Kucharz J, Dumnicka P, Kuzniewski M, Herman RM, Zygulska AL, Kusnierz\u2013Cabala B (2017) Sunitinib\u2013induced hypothyroidism predicts progression\u2013free survival in metastatic renal cell carcinoma patients. Med Oncol 34(4):68","journal-title":"Med Oncol"},{"key":"328_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"issue":"2","key":"328_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/02841860701765675","volume":"47","author":"D Chu","year":"2008","unstructured":"Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand\u2013foot skin reaction with sorafenib: a systematic review and meta\u2013analysis. Acta Oncol 47(2):176\u2013186","journal-title":"Acta Oncol"},{"key":"328_CR6","unstructured":"ECOG (2018) Eastern cooperative oncology group. Performance status. \n                    https:\/\/www.mdcalc.com\/eastern-cooperative-oncology-group-ecog-performance-status\n                    \n                  . Accessed on 30 Nov 2018"},{"issue":"2","key":"328_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A, Rolland F, Demkow T, Hutson T, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski R, for the TARGET Study Group (2007) Sorafenib in advanced clear\u2013cell renal\u2013cell carcinoma. N Engl J Med 356(2):125\u2013134","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"328_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux\u2013Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A, ESMO Guidelines Committee (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2013up. Ann Oncol 27(suppl 5):58\u201368","journal-title":"Ann Oncol"},{"issue":"5","key":"328_CR9","first-page":"494","volume":"16","author":"M Janusch","year":"2006","unstructured":"Janusch M, Fischer M, Marsch WC, Holzhausen HJ, Kegel T, Helmbold P (2006) The hand\u2013foot syndrome \u2013 a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 16(5):494\u2013499","journal-title":"Eur J Dermatol"},{"issue":"10","key":"328_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12032-016-0818-9","volume":"33","author":"J Kucharz","year":"2016","unstructured":"Kucharz J, Giza A, Dumnicka P, Kuzniewski M, Kusnierz\u2013Cabala B, Bryniarski P, Herman R, Zygulska AL, Krzemieniecki K (2016) Macrocytosis during sunitinib treatment predicts progression\u2013free survival in patients with metastatic renal cell carcinoma. Med Oncol 33(10):109","journal-title":"Med Oncol"},{"key":"328_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.09.016","volume":"119","author":"J Li","year":"2017","unstructured":"Li J, Gu J (2017) Hand\u2013foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta\u2013analysis. Crit Rev Oncol Hematol 119:50\u201358","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"328_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000258880","volume":"77","author":"AD Lipworth","year":"2009","unstructured":"Lipworth AD, Robert C, Zhu AX (2009) Hand\u2013foot syndrome (hand\u2013foot skin reaction, palmar\u2013plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5):257\u2013271","journal-title":"Oncology"},{"issue":"7","key":"328_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin\u2013related palmar\u2013plantar erythrodysesthesia (\u2018hand\u2013foot\u2019 syndrome). Ann Oncol 18(7):1159\u20131164","journal-title":"Ann Oncol"},{"issue":"1","key":"328_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12885-018-4209-9","volume":"18","author":"A Mar\u00e1z","year":"2018","unstructured":"Mar\u00e1z A, Cserh\u00e1ti A, Uhercs\u00e1k G, Szil\u00e1gyi \u00c9, Varga Z, R\u00e9v\u00e9sz J, K\u00f3sz\u00f3 R, Varga L, Kah\u00e1n Z (2018) Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer 18(1):296","journal-title":"BMC Cancer"},{"issue":"Suppl 7","key":"328_CR15","doi-asserted-by":"publisher","first-page":"Abstr 320","DOI":"10.1200\/jco.2011.29.7_suppl.320","volume":"29","author":"MD Michaelson","year":"2011","unstructured":"Michaelson MD, Cohen DP, Li S, Motzer RJ, Escudier B, Barrios CH, Burnett PE, Puzanov I (2011) Handfoot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). J Clin Oncol 29(Suppl 7):Abstr 320","journal-title":"J Clin Oncol"},{"issue":"8","key":"328_CR16","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530\u20132540","journal-title":"J Clin Oncol"},{"key":"328_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal\u2013cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"issue":"10","key":"328_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jjco\/hyt110","volume":"43","author":"K Nakano","year":"2013","unstructured":"Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T (2013) Hand\u2013foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol 43(10):1023\u20131029","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"328_CR19","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1093\/annonc\/mds145","volume":"23","author":"A Poprach","year":"2012","unstructured":"Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, Czech Renal Cancer Cooperative Group (2012) Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry\u2013based study. Ann Oncol 23(12):3137\u20133143","journal-title":"Ann Oncol"},{"key":"328_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5114\/ceji.2016.63132","volume":"41","author":"D Po\u017carowska","year":"2016","unstructured":"Po\u017carowska D, Po\u017carowski P (2016) The era of anti\u2013vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti\u2013VEGF therapy. Cent Eur J Immunol 41:311\u2013316","journal-title":"Cent Eur J Immunol"},{"key":"328_CR21","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1093\/annonc\/mdt288","volume":"24","author":"A Ravaud","year":"2013","unstructured":"Ravaud A, Schmidinger M (2013) Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol 24:2935\u20132942","journal-title":"Ann Oncol"},{"issue":"3","key":"328_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cncr.25422","volume":"117","author":"Manuela Schmidinger","year":"2010","unstructured":"Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse. Cancer 117(3):534\u2013544","journal-title":"Cancer"},{"key":"328_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5114\/ceji.2016.59739","volume":"41","author":"M Wyganowska\u2013Swiatkowska","year":"2016","unstructured":"Wyganowska\u2013Swiatkowska M, Urbaniak P, Szkaradkiewicz A, Jankun J, Kotwicka M (2016) Effects of chlorhexidine, essential oils and herbal medicines (salvia, chamomile, calendula) on human fibroblast in vitro. Cent Eur J Immunol 41:125\u2013131","journal-title":"Cent Eur J Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Advances in Medicine and Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2018_328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T18:46:00Z","timestamp":1558118760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2018_328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030129224","9783030129231"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/5584_2018_328","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"31 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}